Potential Treatment With Triciribine for Two Fatal Lung Diseases

by Dr. Trupti Shirole on  June 15, 2015 at 10:21 AM Respiratory Disease News   - G J E 4
Pulmonary fibrosis and pulmonary hypertension are two fatal respiratory diseases. Pulmonary fibrosis occurs when the lung tissue becomes scarred, leading to loss of lung functioning and reduced oxygen supply to the blood, while pulmonary hypertension involves an increase of blood pressure in the arteries of the lung that can lead to heart failure. Researchers have now discovered that the drug triciribine may reverse or halt the progression of both these conditions.
Potential Treatment With Triciribine for Two Fatal Lung Diseases
Potential Treatment With Triciribine for Two Fatal Lung Diseases

Somanath Shenoy, associate professor at the University of Georgia's College of Pharmacy and co-author of the study, said, "Our tests show that treatment with triciribine can halt disease progression and may even reverse some of the damage to lung tissue."

For the study, researchers used mouse models that mimic the disease characteristics of pulmonary hypertension and pulmonary fibrosis in humans. The drug triciribine inhibits production of a protein called Akt1. Once the mice began to exhibit symptoms of the disease, the scientists injected the mice with triciribine once daily for a period of three weeks. It was seen that the characteristic scarring and loss of lung vasculature was slowed in every mouse and the lung tissue of some mice began to return to normal.

Shenoy said, "To our knowledge, this is the first direct evidence that Akt1 causes disease onset and progression of pulmonary fibrosis and pulmonary hypertension. We have also tested this process in human cells taken from diseased lung tissue and noted very similar results."

The researchers tested their hypothesis further by examining genetically modified mice who do not possess the Akt1 pathway. None of these mice developed the disease symptoms, further implicating Akt1 as the primary cause of disease. Shenoy said, "We still need to identify the downstream effects of Akt1 inhibition to see if there are any negative side effects. But if these tests go well, we hope to begin human trials within the next three to five years."

The study appeared in the British Journal of Pharmacology.

Source: IANS

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

More News on: